Recently, Lee SJ et al. [1] showed that unrelated bone marrow transplantation (uBMT) was favored because patients who underwent BMT had less long-term complications such as chronic graft-versus-host disease (GVHD) than those who underwent unrelated peripheral blood stem cell transplantation (uPBSCT). In order to prevent longterm complications, it is crucial to establish a strategy to effectively prevent severe chronic GVHD after PBSCT without compromising overall survival (OS). Although anti-T lymphocyte globulin (ATG) might be an option to prevent chronic GVHD, there is still controversy regarding the benefit of ATG [2, 3] . The use of high ATG doses can lead to profound depletion of donor-derived T cells, which can increase the risk of viral infection and attenuate graft-vs.-leukemia effects. Since T-cell profiles vary significantly among stem cell sources, the optimal ATG dose might also differ. We previously reported that use of low-dose ATG-Thymoglobulin (ATG-T; median dose, 1.5 mg/kg) was associated with a lower incidence of severe/refractory chronic GVHD and superior GVHD-free, relapse-free survival (GRFS) in unrelated hematopoietic stem cell transplantation (HSCT), and 98% of patients received uBMT in this study [4] .
To evaluate the impact of low-dose ATG-T on clinical outcomes in unrelated HSCT including both uBMT and uPBSCT, we performed a single-center, retrospective analysis of 232 patients with hematological disorders who received unrelated HSCT at the National Cancer Center Hospital from 2012 to 2016 (uBMT, n = 199; uPBSCT, n = 33). This study was approved by the Institutional Review Board of the National Cancer Center, Tokyo, Japan. In this cohort, all patients in the ATG-T group received rabbit ATG (Thymoglobulin; Genzyme-Sanofi, Lyon, France). Acute and chronic GVHD and GRFS were defined according to previously published criteria [5] [6] [7] . Chronic lung dysfunction was diagnosed with computed tomography and a respiratory function test according to Bacigalupo's report [8] . The probability of OS and GRFS were calculated using the Kaplan-Meier method, and groups were compared using the log-rank test. The cumulative incidences of NRM, relapse, acute GVHD, chronic GVHD, and viral infection were calculated by Gray's method. In the competing risk models for GVHD and viral infection, relapse and death before these events were defined as competing risks. In the competing risk models for NRM, relapse was defined as competing risk. The variables that were evaluated in these analysis were as follows: patient age at transplant (age ≥ 40 vs. age < 40), patient gender (male vs. female), ECOG performance status (0-1 vs. 2-4), disease status (CR vs. non-CR), disease risk index (DRI) (low vs. intermediate vs. high vs. very high) [9] , hematopoietic cell transplantation-comorbidity index (HCT-CI) score (0 vs. 1-2 vs. ≥3) [10] , intensity of the conditioning regimen (myeloablative conditioning [MAC] vs. reduced-intensity conditioning [RIC]), ATG as GVHD prophylaxis (yes vs. no), HLA disparity assessed by allele typing of HLA-A, B, C, and DRB1 in the GVH-direction (none vs. 1 allele vs. [11] . The characteristics of the 232 patients are shown in Table 1 . Surviving patients were followed-up for a median of 793 days after HSCT (uBMT, 895 days; uPBSCT, 350 days). The proportions of patients who received ATG-T were 23.1% in uBMT and 60.6% in uPBSCT (P < 0.001). The median total dose of ATG-T was 1.5 mg/kg (range 0.9-6.0 mg/kg) in uBMT and 1.5 mg/kg (range 1.0-3.0 mg/ kg) in uPBSCT.
The probabilities of 1-year OS were 71.7% after uBMT and 70.1% after uPBSCT (P = 0.340; Fig. 1a) . The 1-year cumulative incidences of moderate/severe chronic GVHD were 28.1% and 25.0% after uBMT and uPBSCT, respectively (P = 0.610; Fig. 1b ) and those of chronic lung dysfunction were 7.3% and 6.9% after uBMT and uPBSCT, respectively (P = 0.924; Fig. S1A ). There were no statistically significant differences in the rate of relapse, NRM, acute GVHD (grade II-IV, grade III-IV) or GRFS between uBMT and uPBSCT (Fig. S1B-1E and Fig. 1c) .
In all patients, the 1-year cumulative incidences of moderate/severe chronic GVHD were 31.1% and 18.6% in the non-ATG-T and ATG-T groups, respectively, (P = 0.027; Fig. 1d ). In the univariate and multivariate analyses, uBMT unrelated bone marrow transplantation, uPBSCT unrelated peripheral blood stem cell transplantation, ATG anti-thymocyte globulin, MDS myelodysplastic syndrome, ATL adult T-cell leukemia, CR complete remission, HCT-CI hematopoietic cell transplantation-comorbidity index, RIC reduced-intensity conditioning, MAC myeloablative conditioning, CMV cytomegalovirus the use of ATG-T was associated only with lower incidences of both chronic GVHD and moderate/severe chronic GVHD (Table S1 ). There was no statistically significant difference between the non-ATG-T and ATG-T groups in the incidence of cytomegalovirus disease (10.9% vs. 9.1%), adenovirus disease (1.8% vs. 1.5%) or BK virus disease (3.1% vs. 2.4%). No patients developed post-transplant lymphoproliferative disorder. In the non-ATG-T and ATG-T groups, the respective 1-year cumulative incidences of relapse were 27.1% and 17.6% (P = 0.195; Fig. S2A ) overall, 24.0 and 14.5% in patients who received a MAC regimen (P = 0.473; Fig. S2B ) and 29.8 and 18.4% in those who received a RIC regimen (P = 0.164; Fig. S2C ). In the univariate and multivariate analyses, DRI, performance status and HLA disparity were associated with relapse, NRM and OS. Neither the use of ATG-T or stem cell source was significantly associated with the incidence of relapse, the incidence of NRM or OS (Tables S2 and S3) . 
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In patients who received uBMT, the respective 1-year cumulative incidences of chronic GVHD were 38.6 and 25.0% (P = 0.040; Fig. S2D ), those of moderate/severe chronic GVHD were 29.7 and 22.8% (P = 0.188; Fig. 1e ) and those of chronic lung dysfunction were 9.4 and 0.0% (P = 0.029; Fig. S3A ) in the non-ATG-T and ATG-T groups. The 1-year GRFS rates were 36.7% and 59.7% in the non-ATG-T and ATG-T groups, respectively (P = 0.009; Fig. 1f ). There were no differences in the rate of relapse, OS, NRM or acute GVHD between the two groups ( Fig. S3B-3F) .
In patients who received uPBSCT, the respective 1-year cumulative incidences of chronic GVHD were 53.8 and 23.4% (P = 0.153; Fig. S2D ), those of moderate/severe chronic GVHD were 46.2 and 6.1% (P = 0.016; Fig. 1e ) and those of chronic lung dysfunction were 15.4 and 0.0% (P = 0.109; Fig. S4A ) in the non-ATG-T and ATG-T groups. The 1-year GRFS rates were 15.4% and 66.7% in the non-ATG-T and ATG-T groups, respectively (P = 0.034; Fig. 1f ). There were no statistically significant differences in the rate of relapse, OS, NRM or grade II-IV acute GVHD between the two groups ( Fig. S4B-4E ). No patients developed grade III-IV acute GVHD.
Here, we found that the use of low-dose ATG-T might be beneficial in unrelated HSCT, including both BMT and PBSCT. It is well-known that uPBSCT is associated with a higher risk of chronic GVHD and a lower GRFS in comparison to uBMT [1] . However, in the current study, there was no statistically significant difference in the risk of moderate/severe chronic GVHD or GRFS between uBMT and uPBSCT, as shown in Fig. 1b, c , although the sample size was rather small. This might be because ATG-T was used in a majority of patients who received uPBSCT. The incidence of moderate/severe chronic GVHD in uPBSCT seemed to be effectively reduced by ATG-T, as only the use of ATG-T was associated with lower rates of chronic GVHD and moderate/severe chronic GVHD. Low-dose ATG-T (median 1.5 mg/kg) reduced the risk of GVHD without compromising OS regardless of the conditioning regimen intensity, and this resulted in a comparable GRFS after uPBSCT as that after uBMT. In order to confirm these beneficial effects, larger prospective studies are warranted.
The mechanism whereby such low-dose ATG-T reduced the risk of GVHD without compromising OS should be discussed. First, the risk of GVHD might differ among ethnicities and races. Asian populations were reported to have a lower risk of GVHD compared to Caucasian populations [12] . A Korean study showed that 2.5 mg/kg of ATG-T effectively reduced the incidence of GVHD [13] , and our previous study showed that low-dose ATG was associated with a lower risk of chronic GVHD [4] . On the other hand, a French study showed that 2.5 mg/kg of ATG-T was not sufficient to reduce GVHD compared with 5.0 mg/kg of ATG-T [14] . Second, previous studies reported that ATG has immunomodulatory effects and these might reduce the risk of GVHD independent of T-cell depletion and irrespective of ATG dose [15] . This study had several limitations. First, the number of patients who received uPBSCT was small, and our study cohort was not well balanced due to its retrospective nature. Second, in uBMT, the proportion of patients who received ATG-T was lower in patients with high DRI, possibly because the participating physicians believed that ATG might increase the risk of relapse in this population. Therefore, the overall outcome was inferior in patients without ATG-T partly because of the difference in the disease risk.
In conclusion, use of low-dose ATG-T might be beneficial not only in uBMT but also in uPBSCT. Further investigation of low-dose ATG-T as prophylaxis for GVHD is warranted in prospective clinical trials.
